Dare Bioscience, Inc.

Daré Bioscience, Inc. is a health biotechnology company focused on developing solutions for women's health. The company aims to bridge the gap between scientific advancements and practical applications in areas such as contraception, menopause, pelvic pain, fertility, vaginal health, and infectious diseases. Daré operates as a female-led organization, concentrating on accelerating the development of science-based solutions that meet clinical rigor standards, including randomized, controlled trials, validated endpoints, peer-reviewed publications, and current Good Manufacturing Practice (cGMP) requirements. The company's objective is to introduce innovative products to the market, either as FDA-approved therapies or through alternative regulatory pathways like Section 503B compounding, to ensure earlier availability. Daré maintains a pipeline of investigational products and near-commercial products available through alternative pathways. In March 2025, the company expanded its business model to incorporate a dual-path approach for bringing new products to market.